References
- Dean JH, Luster MI, Boorman GA, Lauer LD. 1982. Procedures available to examine the immunotoxicity of chemicals and drugs. Pharmacol Rev. 34:137–148.
- Everds NE, Snyder PW, Bailey KL, Bolon B, Creasy DM, Foley GL, Rosol TJ, Sellers T. 2013. Interpreting stress responses during routine toxicity studies: A review of the biology, impact and assessment. Toxicol Pathol. 41:560–614.
- Haley R. 2003. Species differences in structure and function of the immune system. Toxicology. 188:49–71.
- Haley P, Perry R, Ennulat D, Frame S, Johnson C, Lapointe JM, Nyska A, Snyder P, Walker D, Walter G. (STP Immunotoxicology Working Group). 2005. Society of Toxicologic Pathology Position Paper: Best practice guideline for the routine pathology evaluation of the immune system. Toxicol Pathol. 33:404–407.
- Hastings KL. 2002. Implications of the new FDA/CDER immunotoxicology guidance for drugs. Center for Drug Evaluation and Research, US FDA. Intl Immunopharmacol. 2:1613–1618.
- ICICIS Group Investigators. 1998. Report of validation study of assessment of direct immunotoxicity in the rat. Toxicology. 125:183–201.
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2005. ICH Harmonized Tripartite Guideline. Immunotoxicity studies for human pharmaceuticals. Available from: http://www.ich.org/products/guidelines/safety/safety-single/article/immunotoxicity-studies-for-human-pharmaceuticals.html.
- Michael B, Yano B, Sellers RS, Perry R, Morton D, Roome N, Johnson JK, Schafer K, Pitsch S. 2007. Evaluation of organ weights for rodent and non-rodent toxicity studies: A review of regulatory guidelines and a survey of best practices. Toxicol Pathol. 35:742–750.
- Ruehl-Fehlert C, Bradley A, George C, Germann PG, Bollinger AP, Schultee A. 2005. Harmonization of immunotoxicity guidelines in the ICH process – pathology considerations from the guideline Committee of the European Society of Toxicological Pathology (ESTP). Exp Toxicol Pathol. 57:1–5.
- Sellers RS, Morton D, Michael B, Roome N, Johnson JK, Yano BL, Perry R, Schafer K. 2007. Society of Toxicologic Pathology Position Paper: Organ weight recommendations for toxicology studies. Toxicol Pathol. 35:751–755.
- Smialowicz RJ, Luebke RW, Riddle MM, Rogers RR, Rowe DG. 1985. Evaluation of immunotoxic potential of chlordecone with comparison to cyclophosphamide. J Toxicol Environ Health 15:561–574.
- U.S. Food and Drug Administration (FDA), Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). 2002. Guidance for industry. Immunotoxicology evaluation of investigational new drugs. Rockville, MD: FDA. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079239.pdf.